Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Céleste Lebbé"'
Autor:
Gaëlle Farge, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sheenu Chandwani, Caroline Dutriaux, Sophie Dalac, Laurie Levy-Bachelot, Laetitia Verdoni, Emilie Scherrer, Clara Allayous, Céleste Lebbé, Emilie Casarotto, B. Oriano
Publikováno v:
Immunotherapy
Immunotherapy, 2021, 13 (11), pp.905-916. ⟨10.2217/imt-2021-0077⟩
Immunotherapy, 2021, 13 (11), pp.905-916. ⟨10.2217/imt-2021-0077⟩
International audience; Aim: To describe real-world pembrolizumab administration and outcomes for advanced melanoma in France. Materials & methods: Using the MelBase longitudinal database, this multicenter historical-prospective study examined treatm
Autor:
Carlos Gomez-Roca, Sylvie Rottey, Thierry Lesimple, Céleste Lebbé, Ahmad Awada, Celine Pages, Antoine Italiano, Philippe Aftimos, Richard F. Kefford, Armin Schueler, Jean Pierre Delord, Vibeke Kruse, Samantha Goodstal, Nadine Houede, Monica Dinulescu, Suzanne Leijen, Jan H.M. Schellens, Sandrine Faivre, Giorgio Massimini, Eric Raymond
Publikováno v:
Targeted Oncology. 16:47-57
Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients wi
Autor:
Ahmad Awada, Monica Dinulescu, Armin Scheuler, Suzanne Leijen, Jan H.M. Schellens, Nadine Houede, Jean Pierre Delord, Carlos Gomez-Roca, Richard F. Kefford, Giorgio Massimini, Vibeke Kruse, Philippe Aftimos, Thierry Lesimple, Antoine Italiano, Celine Pages, E. Raymond, Sandrine Faivre, Sylvie Rottey, Céleste Lebbé
Publikováno v:
Targeted Oncology. 16:37-46
The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-com
Autor:
Fareeda Hosein, Veerle de Pril, Jon M. Richards, Jean-Jacques Grob, Vanna Chiarion-Sileni, Henrik Schmidt, Virginia Ferraresi, Alessandro Testori, Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Alexander M.M. Eggermont, Paolo A. Ascierto, Stefan Suciu, Caroline Robert, Michael Smylie, Reinhard Dummer, Michal Kicinski, Céleste Lebbé, Michele Maio
Publikováno v:
Eggermont, A M M, Chiarion-Sileni, V, Grob, J J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbe, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Hosein, F, de Pril, V, Kicinski, M, Suciu, S & Testori, A 2019, ' Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma : long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial ', European Journal of Cancer, vol. 119, pp. 1-10 . https://doi.org/10.1016/j.ejca.2019.07.001
Background: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMF
Autor:
Philip Friedlander, Claudia Pföhler, Michael Max Sachse, Max Schlaak, Carola Berking, Lavinia Spain, Alexander M. Menzies, Friedegund Meier, Rafaela Kramer, Kinan Hayani, Céleste Lebbé, Katharina C. Kähler, Lisa Zimmer, Milena Dudda, Anne Zaremba, Alvaro Moreira, Jessica C. Hassel, Georgina V. Long, Barouyr Baroudjian, Lydia Reinhardt, Alison Weppler, Adriana Hepner, Matteo S. Carlino, Carmen Loquai, Paul J Bröckelmann, Anja Gesierich, Tomohiro Enokida, Douglas B. Johnson, Lucie Heinzerling, Thomas Eigentler, Makoto Tahara, Martin Salzmann, Selma Ugurel
Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbea5c242e2582a869d1911e0b68e0cd
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102118984
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102118984
Autor:
Céleste Lebbé, Katharina C. Kähler, Egle Ramelyte, Elisabeth Livingstone, Lucie Heinzerling, Axel Hauschild, Phil F. Cheng, Frédéric Toussaint, Camille L. Gerard, Paolo A. Ascierto, Joanna Mangana, Clara Allayous, Sarah Schäfer, Reinhard Dummer, Anne Zaremba, Jessica C. Hassel, Florentia Dimitriou, Lucia Festino, Olivier Michielin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 149
Background Anti-PD1–based immunotherapy is currently used in most patients with advanced melanoma. Despite the remarkable data regarding overall survival, the optimal treatment duration is still unknown. Methods We evaluated the outcome of 125 pati
Autor:
Kilian Wistuba-Hamprecht, Antje Sucker, Mitchell P. Levesque, Gabriele Madonna, Jason J. Luke, Elva Morretta, Aldo Pinto, Roberta Turiello, Diana Giannarelli, Benjamin Weide, Paolo A. Ascierto, Laurence Imhof, Lucia Festino, Rosa Azzaro, Teresa Amaral, Piotr Rutkowski, Reinhard Dummer, Mariaelena Capone, Céleste Lebbé, Domenico Mallardo, Dirk Schadendorf, Maria Chiara Monti, Silvana Morello, Marc Chevrier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundInhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosin
Autor:
Ragini R. Kudchadkar, Uwe M. Martens, Paul Nghiem, Robert L. Ferris, Julie E. Stein, Junchen Gu, Suzanne L. Topalian, Michi M. Shinohara, Adam Barrows, Christine H. Chung, Rima M. Kulikauskas, Jean Pierre Delord, Lara Dunn, Andrea Horvath, Janis M. Taube, Shailender Bhatia, Lot A. Devriese, William H. Sharfman, Bin Li, Céleste Lebbé, Tian Chen, Asim Amin, Elizabeth L. Engle, Christopher D. Lao
Publikováno v:
J Clin Oncol
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and
Autor:
Vijay Kasturi, Josh Reed, Sarah Flaskett, Elena Benincasa, Paolo A. Ascierto, Giovanni Grignani, Céleste Lebbé, Arne Engelsberg, Paul Nathan, John Walker, Rodrigo Ramella Munhoz, Subramanian Hariharan, Shahneen Sandhu, Eyal Fenig, Luc Dirix
Publikováno v:
Journal for immunotherapy of cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
BackgroundAvelumab, a human anti–programmed death-ligand 1 immunoglobulin G1 monoclonal antibody, showed favorable efficacy and safety in patients with metastatic Merkel cell carcinoma (mMCC) in the phase II JAVELIN Merkel 200 trial, leading to app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04fa5cc67657a7f10de54a742d8d947
https://repository.uantwerpen.be/docstore/d:irua:3784
https://repository.uantwerpen.be/docstore/d:irua:3784
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti